Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients.

ABSTRACT: Molecular alterations underlying Huntington's disease (HD) are not fully elucidated and no curative therapies are available. We have described that increased translation efficiency participates in the motor symptoms in the R6/1 HD mouse model. Here, we evaluated whether sertraline, a widely used antidepressant drug, that modulates translation in cancer cells, could ameliorate motor and cognitive symptoms in HD. We also investigated if alterations in translation efficiency occur in fibroblasts from HD patients and serve as a possible biomarker. As an index of translation efficiency levels, we analyzed puromycin incorporation and phosphorylated 4E-BP1 levels in striatal primary cultures and striatum from R6/1 mice, and in HD patients' fibroblasts, with or without sertraline treatment. Motor

SUBMITTER: Garcia-Forn M 

PROVIDER: S-EPMC12664457 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature